Applied Therapeutics Announces New Equity Offering Agreement

The latest update is out from Applied Therapeutics ( (APLT) ).

On August 29, 2025, Applied Therapeutics, Inc. announced a new Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., allowing the company to sell up to $75 million in common stock. This agreement replaces a previous arrangement with Leerink Partners LLC, which was terminated on the same date. Under the prior agreement, the company had raised approximately $49.3 million from August 11, 2023, to August 29, 2025. The new agreement provides flexibility for future stock offerings, potentially impacting the company’s financial strategy and market positioning.

The most recent analyst rating on (APLT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Spark’s Take on APLT Stock

According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.

Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.

To see Spark’s full report on APLT stock, click here.

More about Applied Therapeutics

Applied Therapeutics, Inc. operates in the biotechnology industry, focusing on developing transformative treatments for patients with high unmet medical needs. The company primarily engages in the research and development of novel drugs targeting diseases with significant market opportunities.

Average Trading Volume: 1,590,799

Technical Sentiment Signal: Sell

Current Market Cap: $73.63M

See more insights into APLT stock on TipRanks’ Stock Analysis page.